Immunocore Files 8-K: Other Events & Financials
Ticker: IMCR · Form: 8-K · Filed: Sep 16, 2024 · CIK: 1671927
| Field | Detail |
|---|---|
| Company | Immunocore Holdings PLC (IMCR) |
| Form Type | 8-K |
| Filed Date | Sep 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, financials
Related Tickers: IMCR
TL;DR
IMCR filed an 8-K, check for updates on events and financials.
AI Summary
Immunocore Holdings plc filed an 8-K on September 16, 2024, reporting on events that occurred on September 14, 2024. The filing includes information on "Other Events" and "Financial Statements and Exhibits." Specific details regarding the nature of these events or financial statements are not provided in the excerpt.
Why It Matters
This filing indicates that Immunocore Holdings plc has made a regulatory submission to the SEC, which may contain material updates relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting events and exhibits, with no immediate indication of significant negative news.
Key Players & Entities
- Immunocore Holdings plc (company) — Registrant
- September 14, 2024 (date) — Date of earliest event reported
- September 16, 2024 (date) — Date of report
FAQ
What specific "Other Events" are being reported by Immunocore Holdings plc?
The provided excerpt does not specify the details of the "Other Events" reported in the 8-K.
What "Financial Statements and Exhibits" are included in this 8-K filing?
The excerpt indicates that financial statements and exhibits are part of the filing, but does not list their specific contents.
What is the significance of the "Date of earliest event reported" being September 14, 2024?
This date signifies the earliest point in time that a material event, which necessitated this 8-K filing, occurred.
What is Immunocore Holdings plc's primary business based on its SIC code?
Immunocore Holdings plc's SIC code is 2836, which corresponds to "BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)".
Where is Immunocore Holdings plc's principal executive office located?
Immunocore Holdings plc's principal executive offices are located at 92 Park Drive, Milton Park, Abingdon, Oxfordshire, United Kingdom, OX14 4RY.
Filing Stats: 597 words · 2 min read · ~2 pages · Grade level 13 · Accepted 2024-09-16 06:46:57
Filing Documents
- ef20035872_8k.htm (8-K) — 32KB
- ef20035872_ex99-1.htm (EX-99.1) — 46KB
- image00002.jpg (GRAPHIC) — 3KB
- image00003.jpg (GRAPHIC) — 11KB
- image00004.jpg (GRAPHIC) — 12KB
- image00005.jpg (GRAPHIC) — 9KB
- 0001140361-24-041100.txt ( ) — 275KB
- imcr-20240914.xsd (EX-101.SCH) — 4KB
- imcr-20240914_lab.xml (EX-101.LAB) — 21KB
- imcr-20240914_pre.xml (EX-101.PRE) — 16KB
- ef20035872_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events On September 14, 2024, Immunocore Holdings plc (the "Company") issued a press release announcing data from the Company's Phase 1 clinical trial of brenetafusp, an ImmTAC bispecific therapy targeting PRAME, in heavily pre-treated patients with ovarian cancer, and translational data of KIMMTRAK and brenetafusp in previously treated, metastatic uveal melanoma patients. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. As disclosed in the press release, on September 14, 2024, the Company presented two posters at the 2024 European Society for Medical Oncology ("ESMO") Congress: one with Phase 1 data of brenetafusp in patients with platinum resistant ovarian cancer and a second with pre-clinical data about the combination of chemotherapy with brenetafusp in cancer cells. On September 16, 2024, the Company will present translational Phase 1/2 data of KIMMTRAK and brenetafusp in previously treated, metastatic uveal melanoma patients during an oral proffered session at the ESMO Congress.
Financial Statements and Exhibits
Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release dated September 14, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNOCORE HOLDINGS PLC Dated: September 16, 2024 By: /s/ Bahija Jallal, Ph.D. Name: Bahija Jallal, Ph.D. Title: Chief Executive Officer